NEW YORK, Nov. 30, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating Theranos, Inc. ("Theranos" or the "Company") for securities fraud and other unlawful business practices. Such investors can obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/theranos.
In 2013, Theranos announced its partnership with Walgreens, that it would offer in-store blood tests at Walgreens locations, and advertised Theranos's "revolutionary" proprietary finger-prick blood-test technology and its benefits. In 2015, Theranos's technology, efficacy and commercial viability began being questioned by journalists and government regulators. In July 2016, Walgreens terminated its partnership with Theranos, and federal regulators have closed Theranos' labs and banned some of Theranos' officers from running labs. Theranos did divulge that a majority of its tests for the past three years have been conducted on conventional equipment, and not on Theranos' much-hyped proprietary technology.
If you are aware of any facts relating to this investigation, you can assist this investigation by visiting the firm's site: www.bgandg.com/theranos. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.